Business
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion REDWOOD CITY,
About this update from Revolution Medicines, Inc.
[{"type":"text","content":"Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion\nREDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Digital RAS-Targeted Drug Discovery Summit being held February 23-25, 2021. Steve Kelsey, M.D., president, research and development, will be a featured speaker during the virtual event and will provide a scientific update on the company’s first-in-class RAS(ON) Inhibitor programs. Revolution Medicines recently announced the entry of two RAS(ON) Inhibitor programs into IND-enabling development: RMC-6291, a potent, oral and selective tri-complex inhibitor of KRASG12C(ON); and RMC-6236 a potent, oral and RAS-selective tri-complex KRASMULTI(ON) inhibitor. Details of Revolution Medicines’ participation in the RAS-Targeted Drug Development Summit are as follows: Presentation: Title:Drugging the RAS(ON) Form of Diverse Oncogenic RAS MutationsPresenter:Steve Kelsey, M.D., president, research and developmentDate:Thursday, February 25, 2021Time:10:30 a.m. Eastern Panel Discussion: Title:Mechanisms of Resistance for Combination TherapiesParticipant:Steve Kelsey, M.D., president, research and developmentDate:Thursday, February 25, 2021Time:11:00 a.m. Eastern Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdiscovery.com/. Revolution Medicines also today announced that the company will participate in three upcoming investor conferences. Details of these events are as follows: 10th Annual SVB Leerink Global Healthcare ConferenceFireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairmanConference date: February 22-26, 2021Fireside chat time: 1:40 – 2:10 p.m. Eastern on February 25, 2021Format: Virtual conference; webcast available 41st Annual Cowen Healthcare ConferenceFireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairmanConference dates: March 1-4, 2021Fireside chat time: 10:20 – 10:50 a.m. Eastern on March 3, 2021Format: Virtual conference; webcast available HC Wainwright Global Life Science ConferenceCorporate...